About

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. They aim to become a global leader in pain management by developing pharmaceutical products responsibly to maximize quality of life. Their portfolio includes FDA-approved products and pipeline candidates targeting various pain conditions.

Key facts

At-a-glance profile data

Website: scilexholding.com
Headquarters: Palo Alto, US
Portfolio companies: 1
Cheque size: $120M to $120M
Sector focus: Pharmaceuticals
Life Sciences
Drug Discovery
Healthcare

Recent investments

Recent funding rounds Scilex Holding Company took part in
Date	Company	Round	Amount
5 May 2026	Datavault AI	Offering of Common Stock	$60M

Scores

Measured, not editorial

Ahrefs DRMeasured by Ahrefs

38/100Below median

Q1 19median 44Q3 71

What this measures

Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.

Check any domain free

API & MCP SecurityMeasured by StartupHub.ai

Measured live, on request

What this measures

What this company’s API or MCP server gives an anonymous stranger: transport, whether anything answers without credentials, CORS, response headers and, when an MCP server replies, which of its tools can be called with no key. Scanned live, on request, because a security verdict months old is worse than none.

Scan this site yourself

Add first review

Frequently asked

What companies has Scilex Holding Company invested in?

Scilex Holding Company has invested in Datavault AI.